Package Leaflet: Information for the User
Zaldiar 37.5 mg/325 mg Film-Coated Tablets
Tramadol Hydrochloride/Paracetamol
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Pack
Zaldiar is a combination of two painkillers, tramadol and paracetamol, which work together to relieve pain.
Zaldiar is indicated for the symptomatic treatment of moderate to severe pain, when your doctor considers that a combination of tramadol and paracetamol is necessary.
Zaldiar should only be used by adults and adolescents over 12 years of age.
Do not take Zaldiar
Warnings and precautions
Consult your doctor before taking Zaldiar, if
Tolerance, dependence, and addiction
This medicine contains tramadol, which is an opioid medicine. Repeated use of opioids can make the medicine less effective (the body gets used to it, which is known as pharmacological tolerance). Repeated use of Zaldiar can also lead to dependence, abuse, and addiction, which can result in a potentially life-threatening overdose. The risk of these side effects may be greater with higher doses and longer use.
Dependence or addiction can cause a feeling of lack of control over the amount of medicine you need to use or how often you need to use it.
The risk of dependence or addiction varies from person to person. The risk of becoming dependent on or addicted to Zaldiar may be greater if:
If you notice any of the following symptoms while taking Zaldiar, it could be a sign of dependence or addiction:
If you notice any of these signs, consult your doctor to determine the best course of treatment for you, when it is appropriate to stop the medicine, and how to do it safely (see section 3, if you stop taking Zaldiar).
Sleep-related breathing disorders
Zaldiar contains an active substance that belongs to the group of opioids. Opioids can cause sleep-related breathing disorders, for example, central sleep apnea (shallow breathing or pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen level in the blood).
The risk of experiencing central sleep apnea depends on the dose of opioids. Your doctor may consider reducing the total dose of opioids if you experience central sleep apnea.
There is a weak risk that you may experience a serotonin syndrome that can occur after taking tramadol in combination with certain antidepressants or tramadol alone. Consult your doctor immediately if you experience any of the symptoms associated with this serious syndrome (see section 4 "Possible side effects").
Tramadol is transformed in the liver by an enzyme. Some people have a variation of this enzyme, and this can affect each person differently. In some people, sufficient pain relief may not be achieved, while others are more likely to experience serious side effects. If you notice any of the following side effects, you must stop taking this medicine and consult your doctor immediately: slow or shallow breathing, confusion, drowsiness, constricted pupils, general malaise, or vomiting, constipation, loss of appetite.
If you have had any of these problems in the past while taking Zaldiar, please inform your doctor. He will decide whether you should continue taking this medicine.
Children and adolescents
Use in children with respiratory problems:
Tramadol is not recommended for use in children with respiratory problems, as the symptoms of tramadol toxicity can worsen in these children.
Tell your doctor if you experience any of the following symptoms while taking Zaldiar:
Extreme fatigue, loss of appetite, severe abdominal pain, nausea, vomiting, or low blood pressure. These may be indicators of adrenal insufficiency (low cortisol levels). If you have these symptoms, contact your doctor, who will decide whether you need to take hormone supplements.
Taking Zaldiar with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Important: This medicine contains paracetamol and tramadol. Tell your doctor if you are taking any other medicine that contains paracetamol or tramadol, so that you do not exceed the maximum daily dose.
Zaldiar must not be takenwith monoamine oxidase inhibitors (MAOIs) (see section "Do not take Zaldiar").
Zaldiar is not recommended if you are being treated with:
Tell your doctor or pharmacist if you are taking:
The risk of side effects increases if you are taking:
Taking Zaldiar with sedative medicines, such as benzodiazepines or related medicines, increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be potentially life-threatening. For this reason, concomitant use should only be considered when other treatment options are not possible. However, if your doctor prescribes this medicine with sedative medicines, you should limit the dose and duration of concomitant treatment.
Tell your doctor about all sedative medicines you are taking and strictly follow your doctor's dosage recommendation. It may be helpful to inform your friends and family about the signs and symptoms mentioned above. Tell your doctor if you experience any of these symptoms.
The effectiveness of Zaldiar may be altered if you also take:
Your doctor will know which medicines are safe to use with Zaldiar.
Taking Zaldiar with food and alcohol
Zaldiar can make you feel drowsy. Alcohol can make you feel drowsy, so it is recommended not to drink alcohol while taking Zaldiar.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Because Zaldiar contains tramadol, it is not recommended to take this medicine during pregnancy or breastfeeding. If you become pregnant during treatment with Zaldiar, consult your doctor before taking the next tablet.
Breastfeeding
Tramadol is excreted in breast milk. For this reason, you should not take Zaldiar more than once during breastfeeding, or if you take Zaldiar more than once, you should interrupt breastfeeding.
Based on human experience, tramadol is not expected to affect fertility in men and women. There are no data available on the combination of tramadol and paracetamol on fertility.
Driving and using machines
Ask your doctor if you can drive or use machines while taking Zaldiar. It is important that before driving or using machines, you observe how this medicine affects you. Do not drive or use machines if you feel drowsy, dizzy, have blurred vision, or double vision, or have difficulty concentrating. Be particularly careful at the start of treatment, after a dose increase, after a change in formulation, and/or when taking it in combination with other medicines.
Zaldiar contains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free".
Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Before starting treatment and regularly during treatment, your doctor will also explain what you can expect from the use of Zaldiar, when and for how long you should use it, when you should contact your doctor, and when you should stop using it (see also section 2).
You should take Zaldiar for the shortest possible time.
Zaldiar is not recommended for use in children under 12 years of age.
The dose should be adjusted according to the intensity of the pain and your individual sensitivity. Normally, the lowest possible dose that produces pain relief should be used.
Unless your doctor has prescribed otherwise, the recommended starting dose for adults and adolescents over 12 years of age is 2 tablets.
If necessary, you can increase the dose, as recommended by your doctor. The shortest interval between doses must be at least 6 hours.
Do not take more than 8 Zaldiar tablets per day.
Do not take Zaldiar more frequently than indicated by your doctor.
Elderly patients
In elderly patients (over 75 years), the elimination of tramadol may be slow. If this is the case, your doctor may recommend prolonging the dosing intervals.
Patients with liver or kidney impairment/patients on dialysis
If you have severe liver or kidney disease, treatment with Zaldiar is not recommended. If you have moderate liver or kidney impairment, your doctor may prolong the dosing intervals.
Method of administration
Zaldiar is available in the form of tablets for oral administration.
The tablets should be swallowed whole with sufficient liquid. They should not be broken or chewed.
If you think the effect of Zaldiar is too strong (e.g., you feel very drowsy or have difficulty breathing) or too weak (e.g., you do not have adequate pain relief), tell your doctor.
If you take more Zaldiar than you should
If you have taken more Zaldiar than you should, even if you feel well, contact your doctor or pharmacist immediately, as there is a risk of serious liver damage that may only become apparent later.
In case of overdose or accidental ingestion, contact the Toxicology Information Service, telephone 91 562 04 20.
If you forget to take Zaldiar
If you forget to take a dose of Zaldiar, it is likely that the pain will return. Do not take a double dose to make up for forgotten doses; simply continue taking the tablets as usual.
If you stop taking Zaldiar
Do not stop taking this medicine suddenly unless your doctor tells you to. If you want to stop taking your medicine, talk to your doctor first, especially if you have been taking it for a long time. Your doctor will inform you when and how to stop it, which can be done by gradually reducing the dose to reduce the likelihood of unnecessary side effects (withdrawal symptoms).
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Very frequent: may affect more than 1 in 10 people;
Frequent: may affect 1 in 10 people;
Infrequent: may affect 1 in 100 people;
Rare: may affect 1 in 1,000 people;
Frequency not known:
The following recognized adverse effects have been reported by people who have taken medications containing only tramadol or only paracetamol. However, if you experience any of these symptoms while taking Zaldiar, you should tell your doctor:
In rare cases, using a medicine like tramadol can create dependence, making it difficult to stop taking it.
In rare cases, people who have been taking tramadol for some time may feel unwell if they suddenly stop treatment. They may feel agitated, anxious, nervous, or trembly. They may be hyperactive, have difficulty sleeping, and have digestive and intestinal disorders. Very few people may also have panic attacks, hallucinations, unusual perceptions such as itching, tingling, and numbness, and ringing in the ears (tinnitus). If you experience any of these symptoms after stopping treatment with Zaldiar, please consult your doctor.
Frequency not known: hiccups.
In exceptional cases, blood tests may reveal certain anomalies, such as low platelet count, which can result in nosebleeds or bleeding in the gums.
In very rare cases, severe skin reactions have been reported with paracetamol.
Rare cases of respiratory depression have been reported with tramadol.
Reporting of Adverse Effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store this medicine in a safe and protected place, where others cannot access it. This medicine can cause serious harm and even be fatal to people who have not been prescribed it.
Do not use this medicine after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated. This medicine does not require special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Zaldiar Composition
Each film-coated tablet contains 37.5 mg of tramadol hydrochloride and 325 mg of paracetamol.
Core of the tablet: powdered cellulose, pregelatinized corn starch, sodium starch glycolate (type A), corn starch, magnesium stearate.
Coating film: hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol 6000, yellow iron oxide (E172), propylene glycol (E1520), talc.
Appearance of the Product and Package Contents
Zaldiar film-coated tablets are pale yellow tablets marked with the manufacturer's logo ? on one side and "T5" on the other.
Zaldiar film-coated tablets are packaged in blisters.
They are available in packages of 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 tablets.
Only some package sizes may be marketed.
Zaldiar film-coated tablets are presented in 2x1, 10x1, 20x1, 30x1, 40x1, 50x1, 60x1, 70x1, 80x1, 90x1, or 100x1 tablet precut unit dose blisters.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Grünenthal Pharma, S.A.
Doctor Zamenhof, 36 – 28027 Madrid, Spain
Manufacturer:
Grünenthal GmbH
Zieglerstrasse 6– D- 52078 Aachen, Germany
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Zaldiar 37,5 mg/325 mg Filmtabletten |
Austria | Zaldiar 37,5 mg/325 mg Filmtabletten |
Belgium | Zaldiar 37,5 mg/325 mg, comprimés pelliculés / filmomhulde tabletten |
Pontalsic 37,5 mg/325 mg, comprimés pelliculés / filmomhulde tabletten | |
Slovenia | Zaldiar 37,5 mg/325 mg filmsko obložene tablete |
Spain | Zaldiar 37,5 mg/325 mg comprimidos recubiertos con película |
Pontalsic 37,5 mg/325 mg comprimidos recubiertos con película | |
France | Zaldiar 37,5 mg/325 mg, comprimé pelliculé |
Ixprim 37,5 mg/325 mg, comprimé pelliculé | |
Greece | ZALDIAR |
Netherlands | Zaldiar 37,5 mg/325 mg, filmomhulde tabletten |
Hungary | Zaldiar 37.5 mg/325 mg filmtabletta |
Ireland | Ixprim 37.5 mg/325 mg, film-coated tablets |
Luxembourg | Zaldiar 37,5 mg/325 mg, comprimés pelliculés |
Portugal | Zaldiar 37,5 mg/325 mg comprimidos revestidos por película |
United Kingdom | Tramacet 37.5 mg/325 mg, film-coated tablets |
Date of the last revision of this prospectus: December 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/